A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma

被引：0
|
作者：
Ikeda, Masafumi [1 ]
Sung, Max W. [2 ]
Kudo, Masatoshi [3 ]
Kobayashi, Masahiro [4 ]
Baron, Ari D. [5 ]
Finn, Richard S. [6 ]
Kaneko, Shuichi [7 ]
Zhu, Andrew X. [8 ]
Kubota, Tomoki [9 ]
Kraljevic, Silvija [10 ]
Ishikawa, Kohei [9 ]
Siegel, Abby B. [11 ]
Kumada, Hiromitsu [4 ]
Young, Louise [12 ]
Okusaka, Takuji [13 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan
[2] Tisch Canc Inst Mt Sinai, New York, NY USA
[3] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[4] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan
[5] Pacific Hematol Oncol Associates, Calif Pacific Med Ctr, San Francisco, CA USA
[6] UCLA Med Ctr, David Geffen Sch Med, Losa Angeles, CA USA
[7] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan
[8] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA
[9] Eisai & Co Ltd, Tokyo, Japan
[10] Eisai Ltd, Hatfield, Herts, England
[11] Merck Co Inc, Kenilworth, NJ USA
[12] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
[13] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
182
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [41] Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
    Chang, Xiujuan
    Yu, Shumin
    Pang, Jianzhi
    Zhang, Wei
    Kong, Huifang
    Huang, Jiagan
    Zhang, Guojie
    Zhang, Huixin
    Gu, Yueyue
    Chen, Yan
    Yang, Bin
    Liu, Jingping
    Zeng, Zhen
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 847 - 861
  • [42] Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
    Chen, Song
    Wu, Zhiqiang
    Shi, Feng
    Mai, Qicong
    Wang, Liguang
    Wang, Fan
    Zhuang, Wenquan
    Chen, Xiaoming
    Chen, Huanwei
    Xu, Bo
    Lai, Jiaming
    Guo, Wenbo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2115 - 2125
  • [43] Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
    Zhao, Shu
    Zhou, Minhang
    Wang, Peng
    Yang, Jing
    Zhang, Dong
    Yin, Fan
    Song, Peng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [44] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [45] Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    Waldschmidt, D.
    El-Khoueir, A. B.
    Kim, R. D.
    Harris, W. P.
    Sung, M. W.
    Iqbal, S.
    Zhang, A.
    Nakajima, K.
    Galle, P. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 123 - 123
  • [46] The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma
    Praktiknjo, Michael
    Solano, Ana S. Pena
    Sadeghlar, Farsaneh
    Welchowski, Thomas
    Schmid, Matthias
    Moehring, Christian
    Zhou, Taotao
    Mahn, Robert
    Monin, Malte B.
    Meyer, Carsten
    Feldmann, Georg
    Brossart, Peter
    van Beekum, Cornelius
    Semaan, Alexander
    Matthaei, Hanno
    Manekeller, Steffen
    Sprinkart, Alois M.
    Nowak, Sebastian
    Luetkens, Julian
    Kalff, Joerg C.
    Strassburg, Christian P.
    Gonzalez-Carmona, Maria A.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [47] LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma
    Llovet, Josep
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina
    Chen, Erluo
    Dubrovsky, Leonid
    Siegel, Abby
    Zhu, Andrew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [48] Effectiveness of transarterial chemoembolization combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma
    Cao, Fei
    Yang, Yi
    Si, Tongguo
    Luo, Jun
    Zeng, Hui
    Zhang, Zhewei
    Chen, Yi
    Zheng, Jiaping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [49] Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
    Hyung-Don Kim
    Seyoung Jung
    Ho Yeong Lim
    Baek-Yeol Ryoo
    Min-Hee Ryu
    Samuel Chuah
    Hong Jae Chon
    Beodeul Kang
    Jung Yong Hong
    Han Chu Lee
    Deok-Bog Moon
    Ki-Hun Kim
    Tae Won Kim
    David Tai
    Valerie Chew
    Jeong Seok Lee
    Richard S. Finn
    June-Young Koh
    Changhoon Yoo
    Nature Medicine, 2024, 30 : 699 - 707
  • [50] Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
    Kim, Hyung-Don
    Jung, Seyoung
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Ryu, Min-Hee
    Chuah, Samuel
    Chon, Hong Jae
    Kang, Beodeul
    Hong, Jung Yong
    Lee, Han Chu
    Moon, Deok-Bog
    Kim, Ki-Hun
    Kim, Tae Won
    Tai, David
    Chew, Valerie
    Lee, Jeong Seok
    Finn, Richard S.
    Koh, June-Young
    Yoo, Changhoon
    NATURE MEDICINE, 2024, 30 (02) : 699 - 707
12345